First Heartland Consultants’s Vertex Pharmaceuticals VRTX Stock Holding History

First Heartland Consultants’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,130	Closed	-$458K	–	432
2021 Q1	$458K	Buy	+2,130	New	+$468K	0.07%	217

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

First Heartland Consultants's VRTX Position: Q2 2021 in Review

First Heartland Consultants sold out of Vertex Pharmaceuticals (VRTX) in Q2 2021, closing a stake of 2,130 shares — an estimated $458K sold.

First Heartland Consultants first reported a position in VRTX in Q1 2021 and held it in 1 quarter. The position peaked at $458K in Q1 2021. 976 funds tracked by Wall St. Rank hold VRTX as of Q2 2021.

First Heartland Consultants reported no remaining Vertex Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
First Heartland Consultants sold 2,130 Vertex Pharmaceuticals shares in Q2 2021, an estimated $458K.
First Heartland Consultants first reported a position in Vertex Pharmaceuticals in Q1 2021 and held it in 1 quarter.
First Heartland Consultants's Vertex Pharmaceuticals position peaked at $458K in Q1 2021.
976 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2021.

Based on First Heartland Consultants's 13F filing for Q2 2021, filed 16 Aug 2021.